Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

JNJ

What Johnson & Johnson Investors Need to Know

Shares of Health Care sector company Johnson & Johnson moved 6.0% today, and are now trading at a price of $164.52. The Large-Cap stock's daily volume was 17,347,668 compared to its average volume of 7,931,980. The S&P 500 index returned a 0.0% performance.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. The company is based in New Brunswick and has 138,100 full time employees. Its market capitalization is $395,846,877,184. Johnson & Johnson currently offers its equity investors a dividend that yields 3.2% per year.

Over the last year, JNJ's share price has increased by 3.8%, which represents a difference of -6.8% when compared to the S&P 500. The stock's 52 week high is $169.99 per share whereas its 52 week low is $140.68. With average free cash flows of $19.24 Billion that have been growing at an average rate of 0.5% over the last 6 years, Johnson & Johnson is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2024 24,266,000 4,424,000 19,842,000 15.46
2023 21,194,000 4,009,000 17,185,000 -13.02
2022 23,410,000 3,652,000 19,758,000 -2.13
2021 23,536,000 3,347,000 20,189,000 1.36
2019 23,416,000 3,498,000 19,918,000 7.48
2018 22,201,000 3,670,000 18,531,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS